C07D 419/14
Containing three or more hetero rings
Official title: containing three or more hetero rings
C07D419/14 (Containing three or more hetero rings) appears on 87 US grants and 143 published applications in this corpus.
Search patents in C07D- Granted patents
- 87
- Published applications
- 143
- Assignees
- 91
- Inventors
- 560
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1994 | 1 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 0 |
| 2003 | 1 | 1 |
| 2004 | 1 | 4 |
| 2005 | 1 | 0 |
| 2006 | 2 | 5 |
| 2007 | 1 | 1 |
| 2008 | 0 | 6 |
| 2009 | 1 | 3 |
| 2010 | 1 | 5 |
| 2011 | 5 | 8 |
| 2012 | 6 | 7 |
| 2013 | 7 | 5 |
| 2014 | 6 | 7 |
| 2015 | 6 | 3 |
| 2016 | 2 | 6 |
| 2017 | 5 | 7 |
| 2018 | 6 | 6 |
| 2019 | 2 | 4 |
| 2020 | 2 | 7 |
| 2021 | 5 | 8 |
| 2022 | 5 | 8 |
| 2023 | 2 | 10 |
| 2024 | 4 | 9 |
| 2025 | 5 | 16 |
| 2026 | 5 | 7 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Inhibitors of myeloperoxidase4 Aug 2026US 12,698,282 B2AstraZeneca AB
- Macrocyclic compounds, a process for their preparation and pharmaceutical compositions containing them2 Jun 2026US 12,643,912 B2Les Laboratoires Servier
- EP2 antagonist compounds12 May 2026US 12,624,024 B2Reservoir Neuroscience, Inc.
- NRF2-activating compound17 Feb 2026US 12,552,757 B2Senju Pharmaceutical Co., Ltd.
- Materials for organic electroluminescent devices13 Jan 2026US 12,522,591 B2Merck Patent GmbH
- Aryl hydrocarbon receptor modulator and use thereof6 Aug 2026US 2026/0226041 A1Arigenx Therapeutics Co., Ltd.
- Compounds with immunomodulatory activity and therapeutic uses thereof30 Jul 2026US 2026/0217665 A1Purdue Research Foundation
- Glp-1 agonists and methods of use4 Jun 2026US 2026/0151392 A1Biolexis Therapeutics, Inc.
- Inhibitors of CDK8 and CDK1916 Apr 2026US 2026/0103458 A1University of Dundee
- Kif18a inhibitors9 Apr 2026US 2026/0098029 A1Amgen Inc.
Most cited
By later US patents
- Compounds and methods for the treatment or prevention of Flavivirus infections65US 6,881,741 B2ViroChem Pharma Inc. · 2005
- Substituted quinazolin-4-ylamine analogues25US 7,074,799 B2Neurogen Corporation · 2006
- Indole, indazole and benzisoxazole compounds23US 5,348,968 AAdir et Compagnie · 1994
- Sulfonamido substituted benzopyran derivatives21US 5,869,478 ABristol-Myers Squibb Company · 1999
- Compositions and methods for inhibition of the JAK pathway20US 8,324,200 B2Rigel Pharmaceuticals, Inc. · 2012